01—Abstract
Summary
Summary of the 10-Q filed November 9, 2012. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a strong third quarter in 2012, demonstrating significant year-over-year growth in both revenue and net income.
Net sales increased by 18.0% to $28.8 milliona, driven by robust demand for their TASER X2 Electronic Control Device (ECD) and increased cartridge sales. The company also saw substantial growth in its emerging Video segment, with sales nearly doubling. Profitability improved considerably, with gross margin expanding to 58.4% from 53.7% in the prior year's quarter, attributable to manufacturing efficiencies and a favorable product mix.
Net income surged by 223.7% to $3.7 millionb, or $0.07 per share. The company's balance sheet remains healthy, with a solid cash position and positive operating cash flow of $23.3 million for the first nine months of the year. However, investors should note the ongoing litigation expenses and the company's stock repurchase program, which utilized $20 million in cash during the period.
02—Key points
Key Highlights
- Net sales increased by 18.0% to $28.8 million in Q3 2012 compared to Q3 2011.
- Net income saw a substantial increase of 223.7% to $3.7 million ($0.07 EPS) in Q3 2012 compared to $1.1 million ($0.02 EPS) in Q3 2011.
- Gross margin improved to 58.4% in Q3 2012 from 53.7% in Q3 2011, driven by manufacturing efficiencies and product mix.
- The TASER X2 ECD and single cartridges were key sales drivers, along with growth in the Video segment (AXON/EVIDENCE.com).
- Operating cash flow for the first nine months of 2012 was strong at $23.3 million.
- The company repurchased $20.0 million of its common stock during the first nine months of 2012.
- Ongoing litigation remains a factor, with specific mention of the Turner case resulting in a $5.5 million judgment against the company, partially covered by insurance.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2012, Axon Enterprise, Inc. kept $0.13.
- Revenue$28.8M100.0%
- Cost of revenue−$12.0M41.6%
- Gross profit$16.8M58.4%
- Operating costs−$11.5M40.1%
- Operating income$5.3M18.3%
- Interest, other & tax−$1.6M5.6%
- Net income$3.7M12.8%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2012filed November 9, 2012Financial Statements
Q3 FY2012 against Q3 FY2011
| Line item | Q3 FY2012Q3 FY2011 | Change |
|---|---|---|
| Revenue | $28.77M$24.38M | +18.0% |
| Cost of Revenue | $11.97M$11.28M | +6.1% |
| Gross Profit | $16.80M$13.10M | +28.2% |
| R&D Expenses | $1.99M$2.36M | −16.0% |
| SG&A Expenses | $9.54M$9.48M | +0.7% |
| Operating Income | $5.28M$1.21M | +335.4% |
| Net Income | $3.68M$1.14M | +223.6% |
| EPS (Basic) | $0.07$0.02 | +250.0% |
| EPS (Diluted) | $0.07$0.02 | +250.0% |
| Shares Outstanding (Basic) | 52.51M58.79M | −10.7% |
| Shares Outstanding (Diluted) | 53.11M60.04M | −11.5% |
05—Questions
Frequently Asked Questions
What were the main drivers of the revenue growth in the third quarter of 2012?
Revenue growth was primarily driven by the continued adoption of the TASER X2 Electronic Control Device (ECD) and an increase in single cartridge sales. The Video segment, including AXON and EVIDENCE.com, also contributed significantly with sales nearly doubling year-over-year.
How has the company's profitability changed compared to the prior year?
Profitability has significantly improved. Gross margin expanded from 53.7% to 58.4% due to manufacturing efficiencies and a more favorable product mix. Net income increased by 223.7% to $3.7 million ($0.07 EPS) in Q3 2012.
What is the company's financial health and liquidity position?
The company's financial health appears strong. They reported $29.1 million in cash, cash equivalents, and investments as of September 30, 2012, and generated $23.3 million in net cash from operating activities for the first nine months of the year. They also have a $10.0 million revolving line of credit available.
What are the significant risks or contingencies the company is facing?
The company is involved in numerous product liability lawsuits related to the use of its TASER devices. While many cases have been dismissed or ruled in favor of the company, there is an ongoing appeal in the Turner case resulting in a $5.5 million judgment. Other risks include potential fluctuations in foreign currency exchange rates and competition.
06—Continue